KOL PANEL DISCUSSION ACR-368 ENDOMETRIAL CANCER TRIAL February 27, 2026 Exhibit 99.1

Forward-looking statements Certain information contained in this presentation and related webcast includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Our forward-looking statements are based primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in the forward-looking statements is subject to risks and uncertainties, including the factors described in our filings with the U.S. Securities and Exchange Commission. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this presentation. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, including those made by the participants of today’s KOL panel, which are made only as of the date of this event. We undertake no obligation to update any forward-looking statements or to reflect new information or the occurrence of unanticipated events, except as required by law.

Today’s agenda Welcome Adam Levy, Ph.D., M.B.A., CFO Introduction Peter Blume-Jensen, M.D., Ph.D., CEO ACR-368 Clinical Data Overview Brian Slomovitz, M.D. Q&A and Discussion Moderator: Mansoor Raza Mirza, M.D., CMO KOL Panelists: Ramez Eskander, M.D. Robert Coleman, M.D. Domenica Lorusso, M.D., Ph.D. Brian Slomovitz, M.D. Audience Q&A All Adjourn Peter Blume-Jensen, M.D., Ph.D., CEO

Today’s Participants Robert Coleman, M.D. GOG Partners, Special Advisor to the President; GOG Foundation, Vice President; Texas Oncology, US Oncology Network; CMO, Vaniam group Brian Slomovitz, M.D. Member of the Board of Directors, GOG Foundation and the Uterine Cancer Lead, GOG Partners; Director of Gynecologic Oncology and Co-chair of the Cancer Research Committee at Mount Sinai Medical Center; Professor of Obstetrics and Gynecology at Florida International University Domenica Lorusso, M.D., Ph.D. Chair, the MITO (Multicenter Italian Trials in Ovarian Cancer and Gynecological Malignancies) Group; Member of ENGOT (European Network of Gynecological Oncological Trial groups); Director of Gynecological Oncology unit at Humanitas Hospital San Pio X, Milan; Professor of Obstetrics and Gynecology, Humanitas University, Rozzano Ramez Eskander, M.D. Julie St. John Endowed chair in Gynecologic Oncology, Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Clinical Trials Medical Director, Fellowship Director – Gynecologic Oncology, UCSD Health, Rebecca and John Moores NCI Designated Comprehensive Cancer Center Mansoor Raza Mirza, M.D. Chief Medical Officer, Acrivon Therapeutics, Former Chief Oncologist at Copenhagen Univ. Hospital; Honorary Congress President of the European Society of Gynecological Oncology (ESGO) Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Co-Founder, Acrivon Therapeutics; Inventor of the AP3 Platform

CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVELY SELECTED BY ONCOSIGNATURE A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296) Panagiotis Konstantinopoulos1, Mihae Song2, Ramez N Eskander3, Daniela Matei4, Ira Winer5, William H Bradley6, Lindsay Brubaker7, Michael Guy8, Donna Mcnamara9, Rachael Turner10, Chrisann Kyi11, Robert L Coleman12, Stephanie Blank13, David M. O'Malley14, Bradley J. Monk15, Katherine Harris16, Monica Phadnis16, Erick Gamelin16, Mansoor Raza Mirza16, Brian Slomovitz17 1Dana-Farber Cancer Institute, Boston, MA, United States, 2City of Hope Comprehensive Cancer Center – Duarte, Duarte, CA, United States, 3UC San Diego Health, San Diego, CA, United States, 4Northwestern Medicine, Chicago, IL, United States, 5Wayne State University/ Karmanos Cancer Institute, Detroit, MI United States, 6Medical College of Wisconsin, Milwaukee, WI, United States, 7University of Colorado Cancer Center, Aurora, CO, United States, 8Miami Valley Hospital South, Centerville, OH, United States, 9John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, United States, 10University of Rochester Medical Center, Rochester, NY, United States, 11Memorial Sloan Kettering Cancer Center, New York, NY, United States, 12Texas Oncology - The Woodlands, The Woodlands, TX, United States, 13Mount Sinai Hospital, New York, NY, United States, 14The Ohio State University Comprehensive Cancer Center - James, Columbus, OH, United States, 15Florida Cancer Specialists & Research Institute, West Palm Beach, FL, United States, 16Acrivon Therapeutics Inc., Watertown, MA, United States, 17Mount Sinai Medical Center, Miami Beach, FL, United States

BM-Stratified Cohorts with Prospective Response Prediction Subjects with high-grade EC ≤3 lines of prior therapy Background, Study Rationale & Design ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos The ACR-368 OncoSignature™ is a tumor agnostic, functional Biomarker (BM) test designed to prospectively predict benefit from ACR-368 (prexasertib), a potent, selective CHK1/2 inhibitor. It is composed of 3 protein biomarkers that measure the tumor’s addiction to CHK1/2-mediated DNA repair independent of genetic alterations. Screening with Acrivon’s OncoSignature BM test across routine-processed (FFPE) human tumor types, predicted endometrial cancer (EC) to be particularly sensitive to ACR-368. Subjects relapsed after prior platinum-based chemotherapy and one prior line of anti-PD-(L)1 therapy Arm 1 (BM+) ACR-368 (105mg/m2 iv q14d) (N=71) Arm 2 (BM-) ACR-368 (105mg/m2 iv q14d) + ULDG* sensitization (10mg/m2 iv q14d) (N=~150) Primary endpoint ORR: RECIST 1.1 *ULDG = ultra low dose gemcitabine Exploratory Arm

ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Subject Demographics Arm 1 (BM+) N = 40 Arm 2 (BM-) N = 48 Median Age (range) 66.0 (40, 77) 66.0 (49, 80) Race, n (%) White 29 (72.5) 29 (60.4) Black/African American 6 (15) 10 (20.8) Asian 1 (2.5) 4 (8.3) American Indian or Alaska Native 0 0 Native Hawaiian or other pacific islander 1 (2.5) 0 Other 1 (2.5) 4 (8.3) Unknown 2 (5) 1 (2.1) Stage, n (%) III 10 (25) 18 (37.5) IV 30 (75) 29 (60.4) Unknown 0 1 (2.1) Histology, n (%) Serous 20 (50) 16 (33.3) Clear-cell carcinoma 2 (5) 4 (8.3) Carcinosarcoma 6 (15) 10 (20.8) Endometroid, G3 9 (22.5) 15 (31.3) Other 3 (7.5) 3 (6.3) ECOG Status at Baseline, n (%) 0 20 (50) 25 (52) 1 20 (50) 23 (48) Subject Demographics Arm 1 (BM+) N = 40 Arm 2 (BM-) N = 48 Median (Mean) Number of Prior Lines 2 (2) 2 (2) Best Overall Response to Last Prior Line Refractory 9 (22.5) 15 (31.3) Relapsed disease 31 (77.5) 33 (68.7) Unknown 0 (0) 0 (0) MMR Status, n (%) pMMR 28 (70) 29 (60.4) dMMR 1 (2.5) 6 (12.5) Unknown 11 (27.5) 13 (27.1) TP53 Status, n (%) Mutant 24 (60) 15 (31.3) Wildtype 6 (15) 11 (22.9) Unknown 10 (25) 22 (45.8) Prior exposure to PD-1/PD-L1, n (%) Yes 39 (97.5) 46 (95.8) No 1 (2.5) 2 (4.2) Prior exposure to Pembro/Len, n (%) Yes 19 (47.5) 20 (41.7) No 21 (52.5) 28 (58.3) Non QC’ed data based on EDC data extract as of 01/13/2026 Demographics and baseline characteristics

Significant Response in Arm 1 (BM+) ITT Population Treated with ACR-368 ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos * Best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025 # # ORR = 39% (95% CI, 24 - 56) n = 31 DCR: 80.6%, CBR (16 weeks): 61.3%​ BOR by RECIST 1.1 on study treatment* Best overall response (BOR) DCR: Disease Control Rate (CR+PR+SD) CBR: Clinical Benefit Rate [(CR+PR)+(SD >16 weeks)]

# # # Better ORR Observed in Subjects with ≤2 Prior lines of Therapy ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos n = 25 n = 35 ORR = 26% (95% CI, 14 - 42) ORR = 44% (95% CI, 27 - 63) Arm 1 (BM+)  ACR-368 ARM 2 (BM-) ACR-368 + ULDG BOR by RECIST 1.1 on study treatment* * Best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025

Significant ORR in Serous All-Comer Population with ≤ 2 Prior Lines of Therapy ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos # # # n = 23 n = 37 Serous (≤ 2 Prior Lines) Non-Serous (≤ 2 Prior Lines) ORR = 22% (95% CI, 11 - 37) ORR = 52% (95% CI, 33 - 71) DCR: 74%, CBR (16 weeks): 65%​ BOR by RECIST 1.1 on study treatment* * Best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025

Favorable Safety Profile ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Treatment-Related Adverse Events N = number of subjects (%) Arm 1 (ACR-368) N=40 Grades 3/4 Arm 2 (ACR-368 + ULDG) N=48 Grades 3/4 Thrombocytopenia 9 (22) 17 (34) Anemia 11 (27) 22 (46) Leukopenia 6 (15) 11 (23) Neutropenia 10 (25) 16 (33) Febrile neutropenia 2 (5) 4 (8) Acute kidney injury 2 (5) 0 TRAEs with Grades 3/4 percentages ≥5% for either group are included in this table. No fatal TRAE in either group. G-CSF is encouraged for ACR-368 monotherapy and mandated for ACR-368 + ULDG Limited, transient, mechanism-based hematological AEs Notable Absence of GI toxicities, ILDs, stomatitis, ocular toxicity, peripheral neuropathy, etc. Data-cut of 01/13/2026

Conclusions ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Subjects relapsed after prior platinum-based chemotherapy and one prior line of anti-PD-(L)1 therapy Arm 1 BM+ N=71 ACR-368 Arm 2 BM- N= up to ~150 ACR-368 with ULDG sensitization Biopsy-Independent Serous Cohort (US + EU) Subjects with ≤2 lines of prior therapy Arm 3 Serous All-Comer N= up to ~90 ACR-368 with ULDG sensitization Enrollment completion Q4 2026 >20 selected sites in 4 major EU countries BM-Stratified Cohorts with Prospective Response Prediction (US only) Subjects with ≤3 lines of prior therapy Primary endpoint ORR by RECIST 1.1 ACR-368 is active in BM+ EC Serous EC shows particularly high ORR in both BM+ and BM- tumors ACR-368 has a favorable safety profile Arm 3 is evaluating ACR-368 with ULDG in serous EC all-comer (biopsy-independent) population with ≤2 prior LoT The study is being expanded to >20 EU sites Primary endpoint ORR by RECIST 1.1 Exploratory Arm LoT: Lines of Therapy

Serous endometrial cancer - a significant unmet need Disproportionate Mortality Accounts for ~40% of all endometrial cancer deaths.5 Limited Effective Treatment Options Only moderate benefit from immunotherapy Chemotherapy responses short-lived. Rapid resistance, early recurrence. HER2-targeting benefits smaller proportion, no TP53-directed therapies Almost all serous patients progress to ≥2nd line of therapy SOC in ≥2nd line post-IO/platinum ~15% ORR and ~3.4 months PFS (single agent chemotherapy)5, 6 Serous EC is characterized by high-grade aplasia and aggressive histological features Nakayama, K.; Nakayama, N.; Ishikawa, M.; Miyazaki, K. Cancers 2012, 4, 799-807. 1SEER database 2https://pmc.ncbi.nlm.nih.gov/articles/PMC9445918 3Concin, C. et al, ESGO–ESTRO–ESP 2025 Guidelines; Lian Y., Luo P. Annals of Global Health (2025). 4Based on internal estimates of approximately 2.4% serous in the prevalence pool given survival approximations 5Bogani et al, Gynecol Oncol. 2021 July ; 162(1): 226–234. doi:10.1016/j.ygyno.2021.04.029. 6Makker et al, NEJM; 2022; 386:437-48 7KOL estimates EC Mortality (US + EU) = ~44K1, 3 Serous EC Mortality 40-50% ~18-22K/year2, 3,7 EC Prevalence ~2.4M patients1, 3 ~58,800 serous EC4